Form 4: Balchem SVP Acquires 2,500 Restricted Shares

George Graham, SVP and Chief R&D Officer of Balchem Corp, acquired 2,500 shares of common stock as restricted stock, vesting over three years.

Summary

• George Graham, the Senior Vice President and Chief R&D Officer of Balchem Corp (BCPC), acquired 2,500 shares of the company's common stock.
• The transaction occurred on October 20, 2025, and involved the acquisition of restricted stock at a price of $0 per share.
• The restricted stock vests ratably over a three-year period: 25% on the first anniversary of the grant date, 25% on the second anniversary, and the remaining 50% on the third anniversary.
• Ownership of these shares is subject to specific transfer restrictions outlined in a Restricted Stock Grant Agreement between Balchem Corp and Mr. Graham.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation event, which is generally positive as it aligns management incentives with shareholder interests. It doesn't suggest any immediate operational or financial changes, but reinforces stability and long-term commitment.

Positives

• The grant of restricted stock aligns the long-term interests of a key executive, George Graham, with those of Balchem Corp's shareholders.
• This form of equity compensation serves as an incentive for executive retention and motivates sustained performance in his role as SVP and Chief R&D Officer.
• The transaction represents a routine and expected component of executive compensation, indicating stable corporate governance practices.

Negatives

• The vesting of these shares will result in a minor, incremental dilution of existing shareholder equity, which is typical for equity compensation plans.

Risks

• The reporting person's full ownership of the 2,500 shares is contingent upon meeting the specified vesting schedule over a three-year period.
• The acquired shares are subject to restrictions on transfer until they are fully vested, as detailed in the Restricted Stock Grant Agreement.

Future Outlook

The vesting schedule for the restricted stock grant provides a clear timeline for the executive's future ownership of these shares, contingent on continued employment and adherence to the grant agreement, thereby aligning long-term incentives.

Industry Context

This transaction is a routine component of executive compensation packages across various industries, particularly in specialty chemicals and nutritional products. It is designed to align management incentives with long-term company performance and shareholder interests, serving as a common tool for executive retention and motivation.

Comparison to Industry Standards

• The utilization of restricted stock as a key element of executive compensation is a widely accepted practice, consistent with compensation strategies observed at peer companies within the specialty chemicals and ingredients sectors.
• A three-year vesting schedule, particularly with a ratable or back-end loaded structure (25%/25%/50%), is a common design for long-term incentive plans, mirroring practices at companies such as Kerry Group, DSM-Firmenich, or Ingredion, which also employ equity grants to retain and incentivize senior talent.
• The grant of 2,500 shares to a Senior Vice President-level executive is within the typical range for a company of Balchem's market capitalization and operational scale, reflecting a standard approach to incentivizing senior leadership.

Related Party Transactions

• Acquisition of 2,500 shares of common stock by George Graham, SVP and Chief R&D Officer, from Balchem Corp as part of an equity compensation plan, constituting a related party transaction.

Stakeholder Impact

• **Shareholders**: The transaction is generally positive as it aligns executive incentives with long-term shareholder value, though it entails minor potential for dilution upon vesting.
• **Employees**: Reinforces the company's commitment to executive retention and performance-based compensation, potentially signaling stability in leadership.
• **Management**: Provides a significant long-term incentive and compensation component for the SVP and Chief R&D Officer, fostering continued dedication to company goals.

Next Steps

• The 2,500 restricted shares will continue to vest over the next three years, with portions vesting on October 20, 2026, October 20, 2027, and October 20, 2028, subject to the terms of the grant agreement.

Key Dates

Recommendation

This Form 4 filing reports a routine restricted stock grant to a senior executive, which is a standard practice for executive compensation and retention. It does not indicate any material changes to the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The transaction aligns executive interests with long-term shareholder value but does not present new information to alter the fundamental investment thesis.

Keywords

Balchem Corp, BCPC, George Graham, SVP, Chief R&D Officer, Restricted Stock, Insider Transaction, Form 4, Equity Compensation, Executive Compensation, Stock Grant, Vesting